×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:TTOO

T2 Biosystems Stock Forecast, Price & News

$0.15
-0.03 (-16.67%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.15
$0.19
50-Day Range
$0.15
$0.49
52-Week Range
$0.15
$1.25
Volume
2.64 million shs
Average Volume
1.72 million shs
Market Capitalization
$25.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.10
30 days | 90 days | 365 days | Advanced Chart

Receive TTOO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter.

TTOO Stock Forecast (MarketRank)

Overall MarketRank

1.97 out of 5 stars

Medical Sector

630th out of 1,418 stocks

Surgical & Medical Instruments Industry

73rd out of 136 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
T2 Biosystems logo

About T2 Biosystems (NASDAQ:TTOO)

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

TTOO Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TTOO
Employees
182
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
6/24/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$1.10
High Stock Price Forecast
$1.50
Low Stock Price Forecast
$0.70
Forecasted Upside/Downside
+633.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-49.24 million
Net Margins
-194.37%
Pretax Margin
-194.37%

Debt

Sales & Book Value

Annual Sales
$28.06 million
Book Value
($0.08) per share

Miscellaneous

Free Float
159,235,000
Market Cap
$25.66 million
Optionable
Optionable
Beta
0.53














T2 Biosystems Frequently Asked Questions

Should I buy or sell T2 Biosystems stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" T2 Biosystems stock.
View analyst ratings for T2 Biosystems
or view top-rated stocks.

What is T2 Biosystems' stock price forecast for 2022?

2 equities research analysts have issued twelve-month price objectives for T2 Biosystems' shares. Their TTOO stock forecasts range from $0.70 to $1.50. On average, they anticipate T2 Biosystems' share price to reach $1.10 in the next twelve months. This suggests a possible upside of 633.3% from the stock's current price.
View analysts' price targets for T2 Biosystems
or view top-rated stocks among Wall Street analysts.

How has T2 Biosystems' stock price performed in 2022?

T2 Biosystems' stock was trading at $0.5162 at the beginning of the year. Since then, TTOO stock has decreased by 70.9% and is now trading at $0.15.
View the best growth stocks for 2022 here
.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for T2 Biosystems
.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) released its quarterly earnings results on Thursday, May, 5th. The medical equipment provider reported ($0.10) EPS for the quarter. The medical equipment provider earned $7.23 million during the quarter. T2 Biosystems had a negative trailing twelve-month return on equity of 1,278.55% and a negative net margin of 194.37%.
View T2 Biosystems' earnings history
.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $28.00 million-$31.00 million, compared to the consensus revenue estimate of $29.47 million.

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the following people:
  • Mr. John J. Sperzel III, B.Sc., Pres, CEO & Chairman (Age 59, Pay $1.03M)
  • Mr. Alec J. Barclay, Sr. VP & COO (Age 42, Pay $544.43k)
  • Mr. Michael Terrence Gibbs Esq., Sr. VP & Gen. Counsel (Age 51, Pay $527.21k) (LinkedIn Profile)
  • Mr. John M. Sprague CPA, Chief Financial Officer (Age 64)
  • Ms. Kelley J. Morgan, Chief People Officer (Age 46)
  • Dr. Aparna Jha Ahuja M.D., Chief Medical Officer & Chairman of Scientific Advisory Board (Age 55)
  • Mr. Brett A. Giffin, Chief Commercial Officer (Age 63)
  • Dr. Roger Smith Ph.D., Sr. VP of Science R&D (Age 57)

What is John McDonough's approval rating as T2 Biosystems' CEO?

36 employees have rated T2 Biosystems CEO John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among T2 Biosystems' employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.94%), State Street Corp (0.38%), Goldman Sachs Group Inc. (0.13%), Principal Financial Group Inc. (0.10%), Commonwealth Equity Services LLC (0.07%) and HNP Capital LLC (0.05%). Company insiders that own T2 Biosystems stock include Adrian M Jones, Alec Barclay, David B Elsbree, Goldman Sachs & Co Llc, John J Sperzel III, John M Sprague, John Mcdonough, Michael Terrence Gibbs and Thomas J Lowery.
View institutional ownership trends for T2 Biosystems
.

Which institutional investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Goldman Sachs Group Inc., Principal Financial Group Inc., Levin Capital Strategies L.P., Simplex Trading LLC, HAP Trading LLC, and Group One Trading L.P.. Company insiders that have sold T2 Biosystems company stock in the last two years include Alec Barclay, John M Sprague, John Mcdonough, and Michael Terrence Gibbs.
View insider buying and selling activity for T2 Biosystems
or view top insider-selling stocks.

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was purchased by a variety of institutional investors in the last quarter, including HNP Capital LLC, State Street Corp, and Commonwealth Equity Services LLC. Company insiders that have bought T2 Biosystems stock in the last two years include Adrian M Jones, Alec Barclay, Goldman Sachs & Co Llc, John J Sperzel III, and Michael Terrence Gibbs.
View insider buying and selling activity for T2 Biosystems
or or view top insider-buying stocks.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $0.15.

How much money does T2 Biosystems make?

T2 Biosystems (NASDAQ:TTOO) has a market capitalization of $25.66 million and generates $28.06 million in revenue each year. The medical equipment provider earns $-49.24 million in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does T2 Biosystems have?

T2 Biosystems employs 182 workers across the globe.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The official website for T2 Biosystems is www.t2biosystems.com. The medical equipment provider can be reached via phone at (781) 761-4646, via email at [email protected], or via fax at 781-357-3080.

This page (NASDAQ:TTOO) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.